Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
On Tuesday, March 10, 2026, PolyPid (NASDAQ:PYPD) presented at The Citizens Life Sciences Conference 2026, highlighting its strategic initiatives and future plans. The conference call underscored the ...
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...
PolyPid Ltd. misses on earnings expectations. Reported EPS is $-0.41 EPS, expectations were $-0.34. Operator: Greetings and welcome to PolyPid’s Fourth Quarter and Full Year 2025 Conference Call.
ATLANTA - Artivion, Inc. (NYSE:AORT), a $1.93 billion market cap medical device company whose shares have surged 31.86% over the past six months, announced new clinical data from two trials evaluating ...
New eTMF module integrates with Enlighten Clinical Solutions’ platform to support inspection-ready clinical trial documentation and execution. ATLANTA, GA, UNITED ...
It has been estimated that from 60 to 70 million Americans have experienced some form of headache. According to the National Headache Foundation, 42 million Americans (28 million of whom are women) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results